Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 in Cystic Fibrosis (F508del Homozygous)
2019-000750-63Phase 2Unknown
- Sponsor
- AbbVie Inc.
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of navocaftor and galicaftor in cystic fibrosis (CF) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Change in lung function from baseline through Day 29. Status: unknown.
02
Drugs
navocaftorgalicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2019-000750-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000750-63.